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BACKGROUND: It is understudied whether the posed association of oral antibiotics with colorectal cancer (CRC) varies between
antibiotic spectrums, colorectal continuum, and if a non-linear dose-dependent relationship is present.
DESIGN: Three electronic databases and a trial platform were searched for all relevant studies, from inception until February 2020,
without restrictions. Random-effects meta-analyses provided pooled effect-sizes (ES) with 95% confidence intervals (CI).
Dose–response analyses modelling the relationship between number of days exposed to antibiotics and CRC risk were extended to
non-linear multivariable random-effects models.
RESULTS: Of 6483 identified publications ten were eligible, including 4.1 million individuals and over 73,550 CRC cases. The pooled
CRC risk was increased among individuals who ever-used antibiotics (ES= 1.17, 95%CI 1.05–1.30), particularly for broad-spectrum
antibiotics (ES= 1.70, 95%CI 1.26–2.30), but not for narrow-spectrum antibiotic (ES= 1.11, 95% 0.93–1.32). The dose–response
analysis did not provide strong evidence of any particular dose–response association, and the risk patterns were rather similar for
colon and rectal cancer.
DISCUSSION: The antibiotic use associated CRC risk seemingly differs between broad- and narrow-spectrum antibiotics, and
possibly within the colorectal continuum. It remains unclear whether this association is causal, requiring more mechanistic studies
and further clarification of drug–microbiome interactions.
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BACKGROUND
Colorectal cancer (CRC) is the fourth most common cause of death
globally,1 accounting for ten percent of all incident cancers and
cancer-related deaths annually.1,2 While the incidence is declining
in several high-income countries,3 a yet unexplained increase
among younger individuals (<50 years) has been observed in
several continents,3–5 making this an important global health
problem. Gut microbes have been associated with CRC promotion,
particularly certain strains of Escherichia coli and Fusobacterium
nucleatum. The latter might even involve a worse prognosis, and
higher treatment resistance, if expressed at high levels.6–8
Antibiotics have been posed as a risk factor for CRC. Besides the
global burden of antibiotic resistance, the high annual antibiotic
consumption (20–50% globally)4,9,10 highlights the need for better
understanding of the possible role of antibiotics and gut
microbiome on the risk of CRC. Emerging evidence supports the
hypothesis of oral antibiotics changing the gut microbiota
composition,11–13 dysregulating critical host immune responses,
and potentially changing important functions of the gut
microbiome.10,11,14,15 These effects on the gut microbiome may be
strong and persistent, possibly leading to chronic inflammation and
tumour progression of even more distal tumour locations.8–10,15–17
However, the association of antibiotics with CRC is complex.
Infection is another major risk factor for cancer globally, contributing
to approximately 16% of annual incident cancers.18,19 Some
evidence indicates that anti-inflammatory drugs may reduce the
risk of cancer,20 further supporting the role of inflammation in
carcinogenesis. Thus, it is also possible that antibiotics could reduce
the risk of cancer, by decreasing inflammation.
Previous meta-analyses have suffered from power limitations
including only five to six studies in total,16,21 pooling together
colon adenoma with carcinoma22, or combining the different
anatomical locations.16,21 None of them considered departure
from linearity, although a recent study suggested for a non-linear
dose–response relationship between antibiotic use and CRC risk.9
There is a clear lack of solid evidence summarising the potential
association of antibiotics with CRC, and current evidence is
insufficient to evaluate whether the potential CRC risk may differ
within the colorectal continuum, or by broad- and narrow-
spectrum antibiotics, indication, age or sex.16,21,22 With the aim
of filling these knowledge gaps, we conducted this comprehen-
sive systematic review and dose–response meta-analysis, evaluat-
ing the risk of CRC among individuals who ever-used antibiotics.
METHODS
This systematic review and meta-analysis was based on an a priori
established study protocol. The results are reported in line with
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the Preferred Reporting Items for Systematic Reviews and Meta-
analyses (PRISMA) guidelines.23
Search strategy and sources
The search strategy consisted of two parts. Firstly, PubMed, Web
of Science and Embase were searched from inception until 17th of
February 2020 to identify all relevant publications reporting data
on the association of oral antibiotics with CRC risk. The search
string was initially optimised with the help of Karolinska Institutet
University Library (Supplementary Table 1), combining Medical
Subject Headings (MeSH-terms) and keywords. Secondly, we
conducted a comprehensive manual search by screening refer-
ence and citation lists of full-text assessed publications, reviews
and editorials, and the Cochrane Central Register of Controlled
Trials database (https://www.cochranelibrary.com/central). No
restrictions were set for the search.
Study selection and eligibility criteria
All data were exported to EndNote X7 and one (JS) author
completed the selection based on publication titles. Two
independent authors (J.S. and N.B.) selected the publications by
assessing the abstracts and full-texts, and any disagreements were
solved by mutual consideration between both authors. One
author (J.S.) extracted summary data from the publications and
another author (R.F.) crosschecked the extracted risk estimates. To
be eligible for this meta-analysis, all following criteria had to be
fulfilled:
1. Study providing original data comparing individuals who
ever-used (i.e., ever-users) antibiotics with nonusers of
antibiotics (0–1 prescriptions), and the risk of primary CRC,
colon or rectal cancer.
2. Cohort study, case–control study or randomised controlled
trial (RCT).
3. Standardised risk estimates were presented as relative risks
(RRs), odds ratios (ORs) or hazard ratios (HRs) with
corresponding 95% confidence intervals (CI), or sufficient
data were available to calculate these.
Following publications were excluded:
1. Animal and in-vitro studies.
2. Study design: cross-sectional studies, case-reports, abstracts,
and reviews, etc.
3. Only pediatric population.
4. Irrelevant exposure or outcome.
In case of publications with overlapping data, the latest
publication was included. If the publication year was the same,
the most comprehensive study was included.
Quality assessment
Two independent authors (J.S. and R.F.) completed the quality
assessment of the included studies, by systematically applying
two quality assessment tools. Newcastle-Ottawa Scale (NOS) tool
for cohort and case–control studies24 had scores ranging between
0 and 9, with a total score of respectively, ≤3, 4–6 and ≥7
considered indicative of low, moderate and high quality.
Additionally, a customised tool for assessing quality and suscept-
ibility to bias in observational studies was applied.25 Quality
assessment was not used to exclude studies.
Data items
For each eligible study, we extracted at minimum the following
data: (1) study characteristics (i.e. author, year, country, study
setting and design, follow-up, risk-estimates, factors adjusted for
in the statistical analyses, funding and conflict of interest related
information), and (2) population characteristic (i.e. age, anatomi-
cal location of CRC, and indication, type and dose of antibiotic
use).
Data synthesis and statistical analysis
We used DerSimonian & Laird random-effects meta-analysis to
pool together the most adjusted risk estimates,26 providing
pooled effect sizes (ES) with 95% CIs for each outcome. Subgroup
analyses were performed by anatomical location, study design,
antibiotic class and antibiotic group (if reported in two or more
studies). Standardised risk estimates (i.e. ORs, RRs and HRs) were
considered equivalent, as the outcome is rare. The included
antibiotic classes were categorised as follows: penicillins, tetra-
cyclines, sulfonamides, macrolides and lincosamides, quinolones,
nitrofurans, cephalosporins, carbapenems, nitroimidazole and
metronidazole, imidazole and others (based on reported data).
Of these, penicillins, metronidazole and lincosamides were
considered narrow-spectrum antibiotics, and the remaining
broad-spectrum antibiotics.
We performed dose–response analyses to assess the relation-
ship between the number of days exposed to any antibiotics/
number of prescriptions and CRC risk. For analyses on the number
of prescriptions, non-users were defined as having received 0–1
prescriptions (based on the available data). This could potentially
dilute the estimates towards null. We used the median of each
prescription category (e.g. 15 prescriptions for category of 10–20
prescriptions) to quantify these as a continuous variable. Firstly,
the dose–response model was fitted within each study and
variance-weighted generalised least squares (GLS) regression
models were used to estimate the pooled study-specific trends.27
Departure from linearity was evaluated by Wald test, with a cut off
of p < 0.05 indicative of non-linearity. We fitted models with cubic
splines and a multivariable random-effects model was used to
pool the study-specific estimates.27 To select the best model fit,
Akaike information criterion (AIC) was applied.26 The I2 statistics
was used to assess statistical across-studies heterogeneity.28
Publication bias and small-study effects26 were assessed using
Egger’s test29 and funnel plots.30
To evaluate the robustness of our results several sensitivity
analyses were undertaken by: (i) excluding a study with selected
population,31 (ii) excluding studies without a clear lag-time of at
least 1-year, (iii) broad- and narrow-spectrum antibiotics, (iv)
excluding/restricting to studies adjusting for non-steroidal anti-
inflammatory drug (NSAID), (v) restricting to studies excluding
patients with inflammatory bowel disease (IBD), and (vi) restricting
to studies excluding patients with Crohn’s disease and ulcerative
colitis. All statistical analyses were performed with STATA MP 15.1.
RESULTS
Included studies
The search identified 6483 publications, and after the selection
process ten studies met the eligibility criteria, including 4,147,560
individuals and over 73,550 CRC cases (Fig. 1).9,31–39 Supplemen-
tary Table 2 presents all excluded, full-text assessed publications.
Supplementary Table 3 presents the outlining characteristics of
the ten included studies. Two were cohort studies36,37 and eight
were case–control studies,9,31–35,38,39 all published in English
between 1998 and 2020. Three studies were conducted in the
United States (N= 3),32,33,37 five in Europe (UK N= 3,9,35,39
Netherlands N= 1,34 Finland N= 136), one in New Zealand38,
and one in Taiwan.31 All publications addressed exposure to oral
antibiotics only.9,31–39 Six studies9,31,34,36,38,39 provided data for
cumulative use (i.e. all antibiotic classes combined), and all but
two studies9,36 provided antibiotic class-specific data (for at least 1
antibiotic class). Five studies provided the number of
prescriptions,9,31,34,35,39 four reported the number of days
exposed,31,34–36 and one study utilised cumulative dose expressed
as tertiles.31 Six studies investigated the risk of primary
CRC,9,34,35,37–39 and five studies provided data for colon
cancer9,31–33,36 and three studies for rectal cancer.9,31,36 All but
three studies reported a clear lag-time of at least 1-year.9,31,32
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The median time elapsed between first antibiotic prescription and
cancer diagnosis was 8 years, ranging between 1 and 15 years.
Quality assessment
The quality of the included publications was considered high
(Supplementary Table 4). In all studies but one,33 drug registries
were used for exposure ascertainment, enabling prospective data
collection and eliminating possible recall bias. The outcome was
identified from registries or clinical databases in all studies.
Although only two studies reported complete coverage of the
region (i.e. >90% of eligible participants),31,36 all studies were
population-based and adjusted for age. Apart from two
publications,33,35 the studies clearly excluded antibiotic prescrip-
tions within one year before cancer diagnosis. Additionally, six
studies clearly excluded patients with predisposing conditions
such as IBD9,34,35,39 or Crohn’s disease and ulcerative colitis.31,33
Antibiotics and risk of colorectal, colon and rectal cancer
For the analysis of antibiotic ever-use versus non-use, eight
publications were included (Fig. 2).9,31–34,37–39 The pooled risk
estimate revealed an increased risk of CRC (effect size ES= 1.17,
95%CI 1.05–1.30, N= 5),9,34,37–39 whilst no clear association were
shown for colon (ES= 1.06, 95%CI 0.89–1.26, N= 4)9,31–33 and
rectal cancer (ES= 1.01, 95%CI 0.96–1.06, N= 2),9,31 based on
fewer studies. The statistical heterogeneity was high for CRC (I2=
95.7%) and colon cancer (I2= 83.5%), but low for rectal cancer
(I2= 2.7%). Pooling of the four case–control studies yielded similar
effect sizes (ES= 1.17, 95%CI 1.05–1.31, I2= 83.5, N= 4) (Supple-
mentary Table 5).9,34,38,39 The funnel plot was visually asymme-
trical towards positive associations, suggesting for presence of
small-study effect (Egger’s test p < 0.0005) (Supplementary Fig. 1a).
The “missing” studies appeared to be in the area of limited
statistical significance (≥90% CI) (Supplementary Fig. 1b).
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Fig. 1 Study selection. A PRISMA Flowchart of the selection of relevant publications included to this meta-analysis.
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The sensitivity analysis restricted to studies excluding patients
with IBD suggested for a potentially higher CRC risk (ES= 1.28, 95%
CI 1.01–1.63, N= 3),9,34,39 whilst no apparent association was shown
for studies excluding patients with Crohn’s disease and ulcerative
colitis (ES= 1.16, 95%CI 0.96–1.40, N= 2)31,33 (Supplementary
Table 5). The association with colon cancer remained unchanged
after removing the publications without a clearly reported lag-time
of at least 1-year.9,31,32 Based on fewer studies, the risk of CRC was
seemingly lower in studies adjusting for NSAID use (ES= 1.06, 95%
CI 1.02–1.11, N= 2),9,34 compared those not adjusting for NSAID
use (ES= 1.26, 95%CI 1.10–1.43, N= 6).31–33,37–39
Antibiotic class-specific risk of colorectal cancer
The various antibiotic classes (reported in eight publications)31–35,37–39
showed different CRC risk estimates (Fig. 3). Compared with non-
users, the pooled risk for ever-users was increased for penicillins (ES=
1.16, 95%CI 1.07–1.25, N= 6),31,33–35,38,39 sulfonamides (ES= 1.17, 95%
CI 1.14–1.20, N= 3),34,35,38 quinolones (ES= 1.23, 95%CI 1.17–1.29,
N= 3),34,35,39 cephalosporins (ES= 1.33, 95%CI 1.15–1.52, N= 3)31,35,37
and nitroimidazole and metronidazole (ES= 1.28, 95%CI 1.10–1.49,
N= 3)32,35,37 (Supplementary Table 5). A marginally increased risk was
found for macrolides and lincosamides (ES= 1.04, 95%CI 1.00–1.08,
N= 4).31,34,35,38 No apparent association was found for other antibiotic
classes. Supplementary Table 6 presents the study-specific estimates
and meta-analytic weights for each study.
Broad- and narrow-spectrum antibiotics. The pooling of broad-
spectrum antibiotics revealed an increased CRC risk (ES= 1.70,
95%CI 1.26–2.30, N= 3)31,34,39 among ever-users, whilst no
apparent association with was shown for narrow-spectrum
antibiotics (ES= 1.11, 95%CI 0.93–1.32, N= 5)31–33,37,39 (Supple-
mentary Table 5).
Dose–response analysis
Five publications reported the number of prescriptions31,34–36,39
and four the number of days exposed to antibiotics9,31,34,35
(Supplementary Table 5.) The risk of colon and rectal cancer
increased with lowest exposure to any antibiotics, following a non-
linear risk pattern (p for non-linearity <0.0005). The risk appeared
to plateau after 30 days of antibiotic use (Fig. 4). The risk patterns
were similar for both colon and rectal cancer, with a stabilised risk
after high cumulative exposure to antibiotics.
DISCUSSION
This largest systematic review and dose–response meta-analysis to
date provides evidence for antibiotic use being associated with an
excess CRC risk, yet the association seemingly differs between
antibiotic classes, and possibly by anatomical location of the
tumour. Furthermore, this study did not find strong evidence of
any particular dose–response association, and the dose–response
patterns were similar for colon and rectal cancer with a stabilised
risk after high cumulative exposure to any antibiotics.
The major advantage of this study is the inclusion of over 4.1
million individuals and over 73,550 primary CRC cases, enhancing
precision compared to previous meta-analyses or single
studies.9,16,21,22 We excluded anal cancers, because they are
commonly originated from squamous cells compared to the
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Fig. 2 Forest plot of the most adjusted relative risks for the association of oral antibiotic use with colorectal cancer risk, ever-users
compared to non-users. ES effect size, 95% CI 95% confidence interval.
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epithelial origin of CRC. In sensitivity analyses, we excluded
patients with IBD, and the data suggested for a potentially
stronger association, yet the inclusion/exclusion of a study39
reporting a more extreme risk estimate influenced the pooled risk
estimates. In all but one study, the exposure and outcome data
were ascertained from registries, eliminating the risk of recall
bias.40 The publications came from developed countries, including
North America, Europe, New Zealand, and Taiwan. The Taiwanese
study was based on type II diabetic patients, which may
unequivocally introduce some selection, and the lifestyle of this
population could differ from the rest of the countries included into
this study (due to Westernisation).31 Overall, the quality of
included the publications was high, based on the Newcastle-
Ottawa Scale and a customised quality assessment tool.
The exposure data were mainly restricted to outpatient care
drugs, excluding intravenous antibiotics, as their impact on gut
microbiota may differ. However, underestimation of exposure due
to over-the-counter drug use is unlikely in highly developed
countries, where systemic antibiotics are available only on
prescription.41 Because of the complexity of the exposure, clinical
and statistical heterogeneity were acceptable, yet the sensitivity
analyses yielded consistent results.
As for all meta-analyses on observational studies, the main
limitations of this study are the inability to infer causality and the
available data and methods of the included studies. However, to
investigate this association by means of a RCT would be
challenging, given a large number of individuals should be
followed-up over longer time period—limiting feasibility. To see
the effects based on real life data, population-based studies offer a
favourable and beneficial approach, yet requiring solid research
methods and valid data-collection. Another general concern in
observational studies is potential residual confounding, and we
lacked data to thoroughly assess confounding by indication. Thus,
we cannot exclude the possibility that some individuals may have
received antibiotics for cancer predisposing conditions, such as
impaired immune and inflammation responses,42,43 or for as of yet
undiagnosed CRC.44 To minimise potential reverse causality,
sensitivity analyses were restricted to publications clearly report-
ing at least 1-year lag-time,33,35 and the association remained
unchanged.
Data were insufficient to compare the risk of left- and right-
sided colon cancer, or to evaluate the effect of indication, age or
menopausal status. Some evidence suggests for left sided-colon
cancer location, particularly in individuals younger than 50
years.4,9 This potential association deserves more attention and
should be confirmed in other large cohort studies.
Another limitation is that the pooled risk estimates in this study
are a mixture of exposures and exposures periods. Despite that,
the majority of the studies had rather similar exposure periods
(starting from the 1990’s), the patterns of use, formulations and
dosages of antibiotics may have changed over time: related to
improved global antibiotic stewardship. Additionally, the duration
of exposure periods varied between the studies, complicating the
interpretation of the pooled risk estimates. Furthermore, con-
sidering the high antibiotic consumption, it is possible that non-
users have received antibiotics during a lifetime (i.e. before the
study period). However, this left censoring and potential
misclassification of exposure would likely be at random among
antibiotic users and non-users, potentially diluting the risk
estimates towards null, rather than explaining the shown
increased CRC risk found for some antibiotic classes.
A risk of detection bias is a concern. Antibiotic users could
utilise the healthcare services more frequently, and it is possible
that antibiotic users could be more likely to participate in potential
screening programmes than non-users. This could result in an
earlier detection of colon adenomas, thus significantly reducing
the risk of developing CRC.45,46 It could also lead to an earlier
detection of CRC, selectively among antibiotic users,42,47
Antibiotic class (number of studies)
Penicillins (N = 6)
Tetracyclines (N = 3)
Subtotal (I-squared = 95.9%, p = 0.000)
Subtotal (I-squared = 0.0%, p = 0.502)
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Nitroimidazole and metronidazole (N = 3)
Subtotal (I-squared = 0.0%, p = 0.926)
Subtotal (I-squared = 50.2%, p = 0.024)
Subtotal (I-squared = 55.8%, p = 0.016)
Subtotal (I-squared = 0.0%, p = 0.606)
Subtotal (I-squared = 94.8%, p = 0.000)
Subtotal (I-squared = 82.0%, p = 0.000)
NOTE: Weights are from random effects analysis
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Fig. 3 Forest plot for the association of antibiotic use with colorectal cancer, stratified by the different antibiotic classes. Antibiotic ever-
users were compared to non-users. ES pooled effect size, 95% CI 95% confidence interval.
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overestimating the CRC risk. However, only two of the included
studies adjusted for screening colonoscopy.9,35
Compared to previous meta-analyses,16,21,22 this present study
is the largest and the first to provide evidence for antibiotic-
spectrum specific risk differences, and to investigate non-linear
dose–response relationship. We also excluded colon adenomas
and divided the colorectal continuum into colon and rectal cancer.
However, the association between antibiotics and CRC risk is
complex, and this study cannot assess the mechanisms underlying
the shown risk differences between the various antibiotic classes.
Considering the different mechanisms of action, one could expect
differences between the various antibiotic classes, and e.g.
quinolones are notorious for DNA-damage. Yet, the microbial
dysbiosis observed among CRC patients in some studies,48
supports the biological plausibility of broad-spectrum antibiotics
having a long-term effect on the gut microbiota, potentially
facilitating colonisation with pathogenic bacteria to a greater
extent than narrow-spectrum antibiotics.43,48–50 Emerging amount
of evidence from human and animal models suggests that
dysbiosis, and particularly some bacteria strains (e.g. Bacterioides
fragilis, Escherichia coli and Fusobacterium nucleatum), might
involve a higher CRC risk through mechanisms increasing cancer
promotion by altering cell proliferation, differentiation and
apoptosis, inflammation, and production of DNA damaging
toxins.6,8,48,51,52 However, if infection and inflammation can
independently promote CRC it is possible that a prolonged
exposure to antibiotics could reduce CRC risk, by reducing
especially chronic inflammation.18 This could be one possible
explanation, or a contributing factor, for the weak non-linear risk
pattern shown in this study. However, a prolonged exposure,
particularly for indications requiring high exposure to antibiotics,
could indicate for a chronic underlying disease. Thus, confounding
by indication cannot be excluded, and since fewer individuals are
likely to be exposed to high cumulative dosages than to lower
dosages, the dose–response data is likely more reliable for those
with lower dosages. Antibiotics have previously been associated
with an increased risk of several cancer types, including breast36,53
and lung cancer,16,42 yet with a decreased risk of ovarian and
cervical cancer.16,54 Although the risk of confounding by indica-
tion cannot be ruled out, it may be more of a concern for lung
cancer, considering the high use of antibiotics for respiratory tract
infections.16,42 Yet, we lacked data on tumour stage and some of
the analyses were limited to fewer studies. Thus, our results should
be interpreted cautiously.
In conclusion, this systematic review and dose–response meta-
analysis suggest that different antibiotic types involve a different
CRC risk. In specific, the excess risk was associated with broad-
spectrum antibiotics, whilst no apparent association was found for
narrow-spectrum antibiotics. The dose–response analysis did not
provide strong evidence of any particular dose–response associa-
tion, and the risk patterns for colon and rectal cancer were similar.
Whereas this study cannot determine causality, the findings raise
questions highlighting the need for more mechanistic studies on
drug–microbiome interactions, and better understanding of the
possible role of antibiotics and microbiome in CRC development.
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